MedTrace Logo

Kidney Damage In Patients With Severe Fall In eGFR

NCT01136915 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-03-17

Study results available
· View outcomes & findings →

Summary

This is a pilot study using a randomized, double blinded, comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have and estimated glomerular filtration \[eGFR\] \< 30 mL/min/1.73 m2. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.

Conditions

  • Coronary Artery Stenosis

Interventions

DRUG

Iopamidol 370

one time administration for PCI

DRUG

Iodixanol 320

Iodixanol 320 single injection for percutaneous coronary injection

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136915 on ClinicalTrials.gov